A Flow Cytometry-Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells

Alex Shepherd1,2, Bigitha Bennychen1,2, Zafer Ahmed1

  • 1Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON, Canada.

Bio-Protocol
|July 1, 2024
PubMed

Insights

This study introduces a simple flow cytometry assay to measure chimeric antigen receptor (CAR) T-cell binding kinetics. The assay quantizes CAR-target cell interactions, aiding the understanding of CAR functionality in cancer therapy.

Area of Science:

  • Immunology
  • Biotechnology
  • Cell Biology

Background:

  • Chimeric antigen receptors (CARs) reprogram immune cells for cancer therapy, particularly in hematological malignancies.
  • Understanding the mechanisms and structural properties governing CAR responses is crucial for optimizing their efficacy.
  • Current knowledge gaps exist regarding the precise factors influencing CAR-mediated cellular interactions and therapeutic outcomes.

Purpose of the Study:

  • To develop and validate a straightforward assay for assessing cellular avidity of CAR-expressing cells.
  • To characterize the interaction kinetics between CAR-expressing T cells and target antigen-expressing cells.
  • To provide a tool for better understanding CAR functionality and signaling events.

Main Methods:

  • Utilized a standard flow cytometer to measure interaction kinetics between CAR-expressing Jurkat cells and target cells.
  • Employed co-culture of CAR Jurkat cells with target-positive and target-negative cells under varying effector-target ratios.
  • Observed the formation of CAR-target cell doublets as a readout of actively bound cells, without the need for staining.

Main Results:

  • Developed a simplified assay to quantify CAR-mediated cellular binding kinetics.
  • Demonstrated that binding curves varied between different CAR constructs based on antigen-binding domains.
  • Confirmed that cellular binding kinetics are consistent, antigen-specific, and require active biological signaling.

Conclusions:

  • The developed assay provides a simple, rapid method to assess CAR-mediated cellular avidity using flow cytometry.
  • This assay can be applied to various CAR targets, including those relevant to solid tumors and hematological cancers.
  • The protocol's ability to reveal unique binding curves aids in understanding CAR-target interactions and proximal signaling, potentially improving CAR-based therapies.